Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Randomized, Double-Blinded, Placebo Controlled, SAD and MAD Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of YR011 Following Oral Administration.

NCT07285967 is registered in ClinicalTrials.gov with Hangzhou Yirui Pharmaceutical Technology Co., Ltd as lead sponsor.

NCT NCT07285967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07285967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Randomized, Double-Blinded, Placebo Controlled, SAD and MAD Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of YR011 Following Oral Administration.
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 1, 2027
Completion date
December 31, 2027
Enrollment
64 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics, safety, tolerability